05:10 AM EDT, 06/14/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was "well-tolerated" and had a safety profile consistent with other treatments of patients with sickle-cell disease, a blood disorder.

The company describes the drug, also called reni-cel, as the first investigational gene-edited cell therapy medicine as a potential treatment for people living with severe sickle-cell disease.

Among 18 patients in the trial of reni-cel, all have been free of vaso-occlusive events for up to 22.8 months of follow-up. Patients showed early normalization of total hemoglobin and sustained improvements in fetal hemoglobin, the company said.

Price: 5.63, Change: +0.14, Percent Change: +2.53